Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Zentalis Pharmaceuticals, Inc. (ZNTL) had Normalized Income after Taxes of $-26.87M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
-- |
|
$-26.87M |
|
-- |
|
-- |
|
$36.06M |
|
$-36.06M |
|
$9.18M |
|
$-26.87M |
|
$-26.87M |
|
$-26.87M |
|
$-26.87M |
|
$-26.87M |
|
|
Normalized Income after Taxes |
$-26.87M |
$-36.06M |
|
$-36.68M |
|
71.99M |
|
71.99M |
|
$-0.37 |
|
$-0.37 |
|
| Balance Sheet Financials | |
$311.60M |
|
$3.09M |
|
$40.11M |
|
$351.71M |
|
$39.02M |
|
-- |
|
$38.19M |
|
$77.21M |
|
$274.50M |
|
$274.50M |
|
$274.50M |
|
72.14M |
|
| Cash Flow Statement Financials | |
$-67.34M |
|
$70.85M |
|
$0.19M |
|
$36.53M |
|
$40.23M |
|
$3.70M |
|
$12.77M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
7.99 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-66.78M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-9.79% |
|
-9.79% |
|
-7.64% |
|
-9.79% |
|
$3.81 |
|
$-0.93 |
|
$-0.94 |
|